NCT02358356View on ClinicalTrials.gov

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Midgut Neuroendocrine TumoursPancreatic Neuroendocrine Tumours
Interventions
DRUG

octreotate

7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)

DRUG

Capecitabine

oral capecitabine 750mg/m2 b.i.d.

DRUG

Temozolomide

temozolomide 75mg/m2 b.i.d.

Trial Locations (4)

2065

Royal North Shore Hospital, St Leonards

4029

Royal Brisbane and Women's Hospital, Herston

6150

Fiona Stanley Hospital, Murdoch

8006

Peter MacCallum Cancer Centre, East Melbourne

All Listed Sponsors
lead

Australasian Gastro-Intestinal Trials Group

NETWORK

NCT02358356 - Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study | Biotech Hunter | Biotech Hunter